A Study to Evaluate the Safety Tolerability and Immunogenicity of a Modified RNA Vaccine Against Influenza
Brief description of study
The purpose of this study is to see if a new type of influenza vaccine, called influenza modRNA vaccine, is safe and can help the body produce antibodies which may help fight off influenza. As influenza modRNA vaccine is investigational (not approved by health authorities), we need to test this type of vaccine using one or two forms of HA as well as testing a quadrivalent influenza modRNA vaccine (qIRV), which targets 4 types of HA. If you are interested in participating in the study, please email nyuvaccinecenter@nyulangone.org .
Clinical Study Identifier: s21-00795
ClinicalTrials.gov Identifier: NCT05052697
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
